[Clinical studies on flomoxef in the perinatal period infections].
We conducted clinical efficacy and safety tests of flomoxef (FMOX, 6315-S) in the perinatal infections and obtained the following results. 1. A total of 25 patients was treated: 16 patients with intrauterine infections, 2 patients with pelvioperitonitis, 4 patients with urinary tract infections and 3 patients with other infections. FMOX was injected at a daily dose of 2-4 g for 3-15 days (6-60 g for total dose) by intravenous drip infusion, intravenous injection or their combination. 2. The clinical efficacy rate was 96.0% of 25 patients: excellent in 4 cases (16.0%), good in 20 cases (80.0%) and poor in 1 case (4.0%). Bacteriological effects obtained were: eradicated in 14/16 cases (87.5%) replaced in 3 cases. 3. There were no subjective or objective side effects, nor were any abnormal laboratory test values attributable to the drug. From these findings, we consider that FMOX treatment appears to obtain good clinical and bacteriological responses and in safe in perinatal period infections.
Chimura
T
T
Department of Obstetrics & Gynecology, School of Medicine, Yamagata University.
Morisaki
N
N
Funayama
T
T
D000328:Adult; D001419:Bacteria / Q000302:isolation & purification; D001991:Bronchitis / Q000188:drug therapy / Q000382:microbiology; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D010538:Peritonitis / Q000188:drug therapy / Q000382:microbiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; C045693:flomoxef